Feasibility and Toxicity of a Modified Dose Intensive R- CODOX-M/IVAC for HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL): Preliminary Results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC).
Author:
Ariela Noy,Lawrence Kaplan,Jeannette Lee
Copyright © 2009 American Society of Hematology